Pharmacotherapeutic options for prediabetes

References

• American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–S28.
   PubMed Web of Science ®Google Scholar
• International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–1334.
   PubMed Web of Science ®Google Scholar
• Colagiuri S, Lee CM, Wong TY, et al. DETECT-2 collaboration writing group. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145–150.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16:155–156.
   PubMed Web of Science ®Google Scholar
• Geneva: World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. 2011
   Google Scholar
• McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J. 1994;308:1323–1328.
   PubMed Web of Science ®Google Scholar
• Hoyer A, Rathmann W, Kuss O. Utility of HbA1c and fasting plasma glucose for screening of type 2 diabetes: a meta-analysis of full ROC curves. Diabet Med. 2018;35:317–322.
   PubMedGoogle Scholar
• Massin P, Lange C, Tichet J. Hemoglobin A1c and fasting plasma glucose levels as predictors of retinopathy at 10 years: the French DESIR study. Arch Ophthalmol. 2011;129:188–195.
   PubMedGoogle Scholar
• Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes. 2011;60:298–305.
   PubMed Web of Science ®Google Scholar
• van Leiden HA, Dekker JM, Moll AC, et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthal. 2003;121:245–251.
   PubMed Web of Science ®Google Scholar
• Lind M, Pivodic A, Svensson AM, et al. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: swedish population based cohort study. BMJ. 2019;366:l4894.
   Google Scholar
• Vajravelu ME, Lee JM. Identifying prediabetes and type 2 diabetes in asymptomatic youth: should HbA1c be used as a diagnostic approach? Curr Diab Rep. 2018;18:43.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006. p. 1–50.
   Google Scholar
• Nathan DM, Mayer BDMB, Ralph A, et al. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care. 2007 Mar;30(3):753–759.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
   Google Scholar
• Michels A, Zhang L, Khadra A. Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention. Pediatr Diabetes. 2015;16:465–484.
   PubMed Web of Science ®Google Scholar
• Bullard KM, Cowie CC, Lessem SE, et al. Prevalence of diagnosed diabetes in adults by diabetes type — United States, 2016. MMWR. 2018;67:359–361.
   PubMed Web of Science ®Google Scholar
• Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82:280–284.
   PubMed Web of Science ®Google Scholar
• Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycemia, insulin sensitivity and insulin secretion preceding the diagnosis of type 2 diabetes: the Whitehall II study. Lancet. 2009;373:2215–2221.
   PubMed Web of Science ®Google Scholar
• Vistisen D, Witte DR, Tabak AG, et al. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II Cohort study. PLoS Med. 2014;11:e1001602.
   PubMed Web of Science ®Google Scholar
• Pan XR, Hu YH, Wang JX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes study. Diabetes Care. 1997;20:537–544.
   PubMed Web of Science ®Google Scholar
• Lindström J, Louheranta A, Mannelin M, et al. The finnish Diabetes Prevention Study (DPS). Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230–3236.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program outcomes study. Lancet Diabetes Endocrinol. 2015;3:866–875.
   PubMed Web of Science ®Google Scholar
• Rendell M, Ross DA, Drew HM, et al. Endogenous insulin secretion measured by C-peptide in maturity onset diabetes controllable by diet alone. Arch Int Med. 1981;141:1617–1622.
   PubMedGoogle Scholar
• Rendell M. C-peptide levels as a criterion in treatment of maturity onset diabetes. J Clin Endo Metab. 1983;57:1198–1206.
   PubMed Web of Science ®Google Scholar
• Rendell M. Editorial: dietary treatment of diabetes mellitus. N Engl J Med. 2000;342:1440–1441.
   PubMed Web of Science ®Google Scholar
• Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diab Endocrinol. 2019;7:344–355.
   PubMed Web of Science ®Google Scholar
• Salas-Salvadó J, Bulló M, Babio N. Reduction in the incidence of type 2 diabetes with the mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care. 2011;34:14–19.
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. No. 288. 2017 Oct.
   Google Scholar
• Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic shaped by global drivers and local environments. Lancet. 2011;378:804–814.
   PubMed Web of Science ®Google Scholar
• Lee T, Dugoua JJ. Nutritional supplements and their effect on glucose control. Curr Diab Rep. 2011;11:142–148.
   PubMed Web of Science ®Google Scholar
• Costello RB, Dwyer JT, Saldanha L, et al. Do cinnamon supplements have a role in glycemic control in type 2 diabetes? A narrative review. J Acad Nutr Diet. 2016;116:1794–1802.
   PubMed Web of Science ®Google Scholar
• Costello RB, Dwyer JT, Bailey RL. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev. 2016;74:455–468.
   PubMed Web of Science ®Google Scholar
• ELDerawi WA, Naser IA, Taleb MH, et al. The effects of oral magnesium supplementation on glycemic response among type 2 diabetes patients. Nutrients. 2018;11:44.
   Web of Science ®Google Scholar
• Palma-Duran SA, Vlassopoulos A, Lean M. Nutritional intervention and impact of polyphenol on glycohemoglobin (HbA1c) in non-diabetic and type 2 diabetic subjects: systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2017 Mar 24;57(5):975–986.
   PubMed Web of Science ®Google Scholar
• Deyno S, Eneyew K, Seyfe S, et al. Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: A meta-analysis and meta-regression. Diabetes Res Clin Pract. 2019;156:107815.
   PubMed Web of Science ®Google Scholar
• Davis PA, Yokoyama W. Cinnamon intake lowers fasting blood glucose: meta-analysis. J Med Food. 2011 Sep;14(9):884–889.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cotillard A, Vatier C, et al. A dietary supplement containing cinnamon, chromium and carnosine decreases fasting plasma glucose and increases lean mass in overweight or obese pre-diabetic subjects: a randomized, placebo-controlled trial. PLoS One. 2015 Sep 25;10(9):e0138646.
   PubMed Web of Science ®Google Scholar
• Ranasinghe P, Wathurapatha WS, Galappatthy P, et al. Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial. J Diabetes. 2018 May;10(5):386–397.
   PubMed Web of Science ®Google Scholar
• Wang X, Wu W, Zheng W, et al. Zinc supplementation improves glycemic control for diabetes prevention and management: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019;110(1):76–90.
   PubMed Web of Science ®Google Scholar
• Islam R, Attia J, Ali L, et al. Zinc supplementation for improving glucose handling in pre-diabetes: a double blind randomized placebo controlled pilot study. Diabetes Res Clin Pract. 2016 May;115:39–46.
   PubMed Web of Science ®Google Scholar
• Pittas AG, Dawson-Hughes B, Sheehan P. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019 Aug 8;381(6):520–530.
   PubMed Web of Science ®Google Scholar
• Davidson MB, Duran P, Lee ML, et al. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care. 2013 Feb;36(2):260–266.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu W, Liu D, et al. Efficacy of Aloe Vera supplementation on prediabetes and early non-treated diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016;8(7):388.
   Web of Science ®Google Scholar
• Gosselin LE, Chrapowitzky L, Todd C, et al. Metabolic effects of α-Lipoic Acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study. Food Funct. 2019 Sep 1;10(9):5732–5738.
   PubMed Web of Science ®Google Scholar
• Zhang XM, Zhang YB, Chi MH. Soy protein supplementation reduces clinical indices in type 2 diabetes and metabolic syndrome. Yonsei Med J. 2016;57:681–689.
   PubMed Web of Science ®Google Scholar
• Demmers A, Korthout H, van Etten-jamaludin FS, et al. Effects of medicinal food plants on impaired glucose tolerance: a systematic review of randomized controlled trials. Diabetes Res Clin Pract. 2017 Sep;131:91–106.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeon YJ. Efficacy and safety of a dieckol-rich extract (AG-dieckol) of brown algae, Ecklonia Cava, in pre-diabetic individuals: a double-blind, randomized, placebo-controlled clinical trial. Food Funct . 2015 Mar;6(3):853–858.
   PubMed Web of Science ®Google Scholar
• Ahn HY, Kim M, Seo C, et al. The effects of Jerusalem artichoke and fermented soybean powder mixture supplementation on blood glucose and oxidative stress in subjects with prediabetes or newly diagnosed type 2 diabetes. Nutr Diabetes. 2018 Jul 19;8(1):42.
   PubMedGoogle Scholar
• Kim JY, Ok HM, Kim J, et al. Mulberry leaf extract improves postprandial glucose response in prediabetic subjects: a randomized, double-blind placebo-controlled trial. J Med Food. 2015 Mar;18(3):306–313.
   PubMed Web of Science ®Google Scholar
• Kassaian N, Feizi A, Aminorroaya A, et al. The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial. Acta Diabetol. 2018 Oct;55(10):1019–1028.
   PubMed Web of Science ®Google Scholar
• Shahdadian F, Mohammadi H, Rouhani MH. Effect of Vitamin K supplementation on glycemic control: a systematic review and meta-analysis of clinical trials. Horm Metab Res. 2018 Mar;50(3):227–235.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290:486–494.
   PubMed Web of Science ®Google Scholar
• Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism. 2006;55:1263–1281.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–1115.
   PubMed Web of Science ®Google Scholar
• DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–1105.
   PubMed Web of Science ®Google Scholar
• Nesto R, Fain R, Li Y, et al. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgrad Med. 2016;128:364–370.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912–921.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161.
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Astrup A, Fujioka K, et al. SCALE obesity prediabetes NN8022-1839 study group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–1409.
   PubMed Web of Science ®Google Scholar
• Ramírez-Rodríguez AM, González-Ortiz M, Martínez-Abundis E. Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes. 2020;128:506–511.
   Google Scholar
• Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22(4):1042–1049.
   PubMed Web of Science ®Google Scholar
• Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673–682.
   PubMed Web of Science ®Google Scholar
• Putz Z, Tabák AG, Tóth N, et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care. 2009;32:181–183.
   PubMed Web of Science ®Google Scholar
• Hoffman-Snyder C, Smith BE, Ross MA, et al. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006;63:1075–1079.
   PubMedGoogle Scholar
• Nebuchennykh M, Løseth S, Jorde R, et al. Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series. Eur J Neurol. 2008;15:810–816.
   PubMed Web of Science ®Google Scholar
• Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448–1453.
   PubMed Web of Science ®Google Scholar
• Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–111.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137–144.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld A, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–649.
   PubMed Web of Science ®Google Scholar
• Brown WV, Fujioka K, Wilson PWF, et al. Obesity: why be concerned? Am J Med. 2009;122(Suppl 1):S4–11.
   PubMedGoogle Scholar
• Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18:715–723.
   PubMed Web of Science ®Google Scholar
• Bastien M, Poirier P, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56:369–381.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Aguilar D, Deswal A, et al. American Heart Association Heart failure and transplantation committee of the council on clinical cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; and Council on Quality and Outcomes Research. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e535–e578.
   PubMed Web of Science ®Google Scholar
• Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
   PubMed Web of Science ®Google Scholar
• Kilov D, Kilov G. Philosophical determinants of obesity as a disease. Obes Rev. 2018;19:41–48.
   PubMed Web of Science ®Google Scholar
• Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695–704.
   PubMed Web of Science ®Google Scholar
• Carlsson L, Sjöholm K, Karlsson C, et al. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity stratified by baseline glucose status. Lancet Diabetes Endocrinol. 2017;5:271–279.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–334.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380::347–357.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380::2295–2306.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–617.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
   PubMed Web of Science ®Google Scholar